Refractory Wilms Tumor
2 clinical trials · Condition
◉ Watch Refractory Wilms Tumor
| Record | Firm | Date |
|---|---|---|
| Trastuzumab Deruxtecan (DS-8201a) for the Treatment of Recurrent or Refractory Osteosarcoma, Wilms Tumor, and Desmoplastic Small Round Cell Tumor (NCT04616560) | National Cancer Institute (NCI) | 2021-03-08 |
| Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors (NCT02867592) | National Cancer Institute (NCI) | 2017-05-18 |
Track Refractory Wilms Tumor automatically
Every clearance here is in the API, with alerts when new ones post.